A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
Call us @: 844 663-3742
Study Details
Medical Condition
Study Phase
Intervention Type
Date
Participation Requirements
Gender
Age
Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Have a question?
You can ask us questions via online form or phone call.
Call us @: 844 663-3742
| Location | Status | Site Contact Details |
|---|
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.
Number of Participants with Adverse Events (AE)
Time Frame: Up to Approximately 140 Days
Maximum Observed Concentration (Cmax)
Time Frame: Up to Approximately 140 Days
Time to Cmax (Tmax)
Time Frame: Up to Approximately 140 Days
Terminal Phase Elimination Rate Constant (β)
Time Frame: Up to Approximately 140 Days
Terminal Phase Elimination Half-life (t1/2)
Time Frame: Up to Approximately 140 Days
Area Under the Concentration-Time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)
Time Frame: Up to Approximately 140 Days
AUC from Time 0 to Infinity (AUCinf)
Time Frame: Up to Approximately 140 Days
Apparent Clearance (CL/F) for Subcutaneous (SC) dosing
Time Frame: Up to Approximately 140 Days
Clearance (CL) for Intravenous (IV) Dosing
Time Frame: Up to Approximately 140 Days
Number of Anti-drug antibody (ADA) Titers
Time Frame: Up to Approximately 140 Days
- Not Available
Interventions:
- Drug: Risankizumab
- Drug: Risankizumab
- Drug: Risankizumab
Enrollment:
30
Additional Information
Watch a video to learn more about what you may experience as a clinical trial volunteer: /resources/what-happens-in-a-clinical-trial
Take a virtual reality screening visit tour to an example of a clinical trial site: /resources/screening-visit-virtual-tour
Use a questionnaire tool to think through questions to ask yourself about participating in a clinical trial and print out your responses to discuss with your partners in your health journey: /resource-information-clinical-trial-community/decision-counselor